Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naratriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 13/20 | 1.00 |
| ▸ | HTR1B known ✓ | P28222 | 13/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | HTR1F | P30939 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naratriptan SCHEMBL68753 | 1.00 | HTR1D (1.00) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL28587084 | 0.99 | HTR1D (0.98) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL41527 | 0.99 | HTR1D (0.98) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL30903899 | 0.99 | HTR1D (0.98) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL12803311 | 0.99 | HTR1D (0.98) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL41528 | 0.98 | HTR1D (0.96) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| SCHEMBL9272206 | 0.94 | HTR1D (0.88) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9274904 | 0.93 | HTR1D (0.86) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| SCHEMBL11946673 | 0.92 | HTR1D (0.84) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| SCHEMBL12936350 | 0.90 | HTR1D (0.81) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387343-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | ICEUTICA PTY LTD (AU) | 2025-12-25 | — | — | US | claimed |
| US-20240122855-A1 | Methods for the preparation of biologically active compounds in nanoparticulate form | ICEUTICA PTY LTD. (AU) | 2024-04-18 | — | — | US | claimed |
| EP-4057999-B1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-12-13 | — | — | EP | claimed |
| US-11819576-B2 | Process for preparing nano-or microparticles comprising a carrier-polymer and one or more biologically active ingredients | EVONIK OPERATIONS GMBH (DE) | 2023-11-21 | — | — | US | claimed |
| US-20230147853-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-05-11 | — | — | US | claimed |
| US-20230147697-A1 | TOPICAL FORMULATIONS HAVING ENHANCED BIOAVAILABILITY | BERG, KARA ANN | 2023-05-11 | — | — | US | claimed |
| EP-4057999-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | Evonik Operations GmbH (DE) | 2022-09-21 | — | — | EP | claimed |
| US-20220054418-A1 | Methods for the preparation of biologically active compounds in nanoparticulate form | ICEUTICA PTY LTD. (AU) | 2022-02-24 | — | — | US | claimed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4696377-A2 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of the University of California (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025262247-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H. LUNDBECK A/S (DK) | 2025-12-26 | — | — | WO | disclosed |
| US-20250387343-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | ICEUTICA PTY LTD (AU) | 2025-12-25 | — | — | US | disclosed |
| EP-4043016-B1 | THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12447144-B2 | 5HT agonists for treating disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4043016-A1 | THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS | The Regents of the University of California (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-4017473-A1 | PHARMACEUTICAL EUTECTIC SALT FORMULATION | SeraNovo Holding B.V. (NL) | 2022-06-29 | — | — | EP | disclosed |
| EP-3989970-A1 | TRIPTAN MICROPORATION DELIVERY SYSTEM | PassPort Technologies, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3261640-B1 | 5HT AGONISTS FOR TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3962455-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2022-03-09 | — | — | EP | disclosed |
| CN-114121154-A | Method for improving aptamer specificity and affinity by utilizing molecular design guidance | 江南大学 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387343-A1 | Nanoparticle Compositions and Methods for Synthesis Thereof | SAMM50, SI, TNNC1 | HTR1D 4618/4885HTR1B 4487/4885HTR1A 4137/4885 |
| US-20220054418-A1 | Methods for the preparation of biologically active compounds in nanoparticulate form | ALPP, ALPG, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HTR1D 4760/4885HTR1B 4064/4885HTR1A 4598/4885 |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | SLC6A4, SLC6A2, TPH2 | HTR1D 37/4885HTR1B 15/4885HTR1A 10/4885 |
| US-12447144-B2 | 5HT agonists for treating disorders | HTR1A, HTR5A, HTR2A | HTR1D 15/4885HTR1B 10/4885HTR1A 1/4885 |
| US-20240122855-A1 | Methods for the preparation of biologically active compounds in nanoparticulate form | ALPP, ALPG, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HTR1D 4760/4885HTR1B 4064/4885HTR1A 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.